Insulin amyloid fibril formation reduction by tripeptide stereoisomers.
Beatrice RosettiSlavko KraljErica ScarelSimone AdorinniBarbara RossiAttilio Vittorio VargiuAna Maria GarciaSilvia MarchesanPublished in: Nanoscale (2024)
Insulin fibrillation is a problem for diabetic patients that can occur during storage and transport, as well as at the subcutaneous injection site, with loss of bioactivity, inflammation, and various adverse effects. Tripeptides are ideal additives to stabilise insulin formulations, thanks to their low cost of production and inherent cytocompatibility. In this work, we analysed the ability of eight tripeptide stereoisomers to inhibit the fibrillation of human insulin in vitro . The sequences contain proline as β-breaker and Phe-Phe as binding motif for the amyloid-prone aromatic triplet found in insulin. Experimental data based on spectroscopy, fluorescence, microscopy, and calorimetric techniques reveal that one stereoisomer is a more effective inhibitor than the others, and cell live/dead assays confirmed its high cytocompatibility. Importantly, in silico data revealed the key regions of insulin engaged in the interaction with this tripeptide, rationalising the molecular mechanism behind insulin fibril formation reduction.
Keyphrases
- type diabetes
- glycemic control
- low cost
- single molecule
- single cell
- endothelial cells
- stem cells
- oxidative stress
- high throughput
- electronic health record
- metabolic syndrome
- adipose tissue
- gene expression
- bone marrow
- mass spectrometry
- mesenchymal stem cells
- artificial intelligence
- binding protein
- molecular docking
- weight loss
- ultrasound guided
- induced pluripotent stem cells
- molecular dynamics simulations